This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES Europe: Oligonucleotide and Peptide Therapeutics

SAVINGS DEADLINE EXPIRES:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
Delivered as Hybrid Event from 16-18 November 2022
Live In-Person Conference Delivered 16-18 NovemberAustria Center Vienna

Lucas Bethge
Vice President and Group Leader Oligonucleot at Silence Therapeutics

Profile

Lucas Bethge studied chemistry at the Humboldt-University zu Berlin (Germany). After he obtained his Ph.D. in 2011 in Bioorganic Chemistry, he first joined NOXXON Pharma. In 2016 he moved to Silence Therapeutics GmbH, a biotech company in Berlin that develops GalNAc-conjugated siRNA for therapeutic use. Currently, he is Vice-President and leading the Oligonucleotide Chemistry group at Silence Therapeutics. Lucas is an expert for the synthesis, modification, and conjugation of oligonucleotides with over ten years of experience in industrial research and development at the interface between early research and clinical development.

Agenda Sessions

  • Towards a Stereo Defined mRNAi Trigger: Phosphordithioates Avoid Undefined Stereo Centres in GalNAc-conjugated siRNA

    10:30